The identification of homogenous subgroups in prodromal Alzheimer’s diseases (AD) can significantly increase the success of clinical trials of anti-amyloid agents. This data analysis, the results of which were presented at AAIC 2016, examined the use of cognitive tests such as CANTAB as a screening tool for Alzheimer's trials.
Data were collected as part of the Roche Scarlet RoAD trial, a randomised control trial of gantenerumab, a fully human monoclonal antibody predominantly targeting aggregated forms of amyloidβ.
This analyses included 1212 subjects all of whom had a deficit on initial cognitive screening tasks - Free and Cued Selective Reminding Test (FCSRT), Mini Mental State Examination (MMSE) and Clinical Dementia Rating (CDR) and had undergone CSF Aβ sampling.
Episodic memory tasks showed good utility for classifying subjects by CSF Aβ level. The FCSRT representing verbal episodic memory and used in initial screening, performed comparatively well across a range of measures; free recall; total recall and index of cueing. The CANTAB episodic memory task, Paired Associates Learning (PAL), also showed good predictive properties.
Interested in learning more about the predictive utility of cognitive measures at screening for determination of CSF Aβ(1-42) status? Download this poster.